Clinical Trial Detail

NCT ID NCT03240016
Title Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

transitional cell carcinoma

Therapies

Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.